United States

Tioga raises $10 million for irritable bowel syndrome trial

Friday, April 13, 2012 01:26 PM

Tioga Pharmaceuticals of San Diego has closed its $10 million Series B equity financing led by new investor Thomas, McNerney & Partners, which invested $8 million in the round.

More... »

Omeros begins enrollment in second phase III OMS302 trial

Wednesday, April 11, 2012 03:52 PM

Omeros, a Seattle-based biopharmaceutical company, has commenced enrollment in a second phase III clinical trial evaluating OMS302 in intraocular lens replacement (ILR) surgery.

More... »

BIND Bioscience releases promising anti-tumor results

Wednesday, April 11, 2012 02:52 PM

BIND Biosciences, a clinical-stage biopharmaceutical company, has releases promising data from an ongoing phase I study of BIND-014, the company’s lead drug candidate within a new class of targeted therapeutics, Accurins, that are programmed to concentrate at tumors.

More... »

Analysis: U.S. CMO market reviving, offering preclinical services

Tuesday, April 10, 2012 11:27 AM

The upturn in the fortunes of pharmaceutical companies after the recession is mirrored by the U.S. contract manufacturing outsourcing (CMO) market, which is expected to grow at a compound annual growth rate of 8.3% from 2011 to 2016, according to Frost & Sullivan's newest analysis of the U.S. CMO market.

More... »

Genstar Capital to acquire ERT

Tuesday, April 10, 2012 11:24 AM

Philadelphia-based eResearch Technology, a technology-driven provider of health outcomes research services to sponsors and CROs, has agreed to be acquired by affiliates of Genstar Capital, a middle market private equity firm, for $8 per share in cash in a transaction valued at approximately $400 million.

More... »

Amgen to acquire KAI Pharmaceuticals

Tuesday, April 10, 2012 11:21 AM

Amgen of Thousand Oaks, Calif., has agreed to acquire South San Francisco-based KAI Pharmaceuticals, a privately held pharmaceutical company.  KAI's lead product candidate, KAI-4169, is a novel agent being initially studied for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis. Amgen will acquire worldwide rights, excluding Japan, to KAI-4169.

More... »

Mytrus rolls out informed consent iPad app

Monday, April 9, 2012 04:44 PM

Mytrus, a San Francisco-based clinical technology and services company, has launched an iPad application explaining informed consent prior to clinical trial patient enrollment.  

More... »

NY Genome Center receives $3 million grant, creates 500 jobs

Monday, April 9, 2012 12:20 PM

The Alfred P. Sloan Foundation has given a $3 million grant to independent non-profit New York Genome Center (NYGC) to help build the infrastructure needed to support a large-scale genome sequencing and bioinformatics facility for translational research.

More... »

EntreMed appoints Ren as interim CEO

Wednesday, April 4, 2012 12:43 PM

EntreMed, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, has appointed Dr. Ken K. Ren as interim CEO, effective April 2, 2012.

More... »

FDA issues new guidance on device approval

Tuesday, March 27, 2012 01:49 PM

The FDA has published its first guidance for medical device manufacturers, describing how the benefits and risks of certain medical devices are considered during pre-market review.

More... »